Formulation Development
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine
PDC*line Pharma recently announced the primary clinical results from the last cohort of patients in its Phase I/II clinical trial with PDC*lung01 (PDC-LUNG-101, NCT03970746), in…
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, recently announced initial clinical data from the ongoing Phase…
Etherna Announces Discovery of Novel mRNA Immunotherapeutic Delivered Via Lipid Nanoparticles That Has Demonstrated Ability to Eradicate Tumors in Preclinical Models
etherna, a biotech company pioneering mRNA and lipid-based-nanoparticle (LNP) technologies, recently announced the publication of pre-clinical data showing the therapeutic potential of a new mixture…
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis
Monte Rosa Therapeutics, Inc. recently announced the closing of its previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs,…
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial
Candel Therapeutics, Inc. recently announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. In the US alone,…
EORTC & Immunocore Announce Enrolment of First Patient Onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
The European Organisation for Research and Treatment of Cancer (EORTC) and Immunocore Holdings plc recently announced the randomization of the first patient in the Phase…
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand RNA Editing Collaboration
ProQR Therapeutics NV recently announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the initial $1 million research grant…
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics Incorporated recently announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly…
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer
BriaCell Therapeutics Corp. will showcased its impressive survival and clinical benefit data in MBC patients, including those with CNS metastases, treated with the Bria-IMT plus…
Enlivex Receives Regulatory Authorization for the Initiation of a Phase 1 Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis
Enlivex Therapeutics Ltd. recently announced the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase 1 trial to evaluate the safety, tolerability, and…
2025 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
FORMULATION FORUM - Nanoparticle Technology for Nose-to-Brain Drug Delivery
Jim Huang, PhD, and Shaukat Ali, PhD, say as we continue our investigation of innovative delivery routes for drug molecules besides the parenteral and oral routes, the IN route remains the future method for drug delivery to the brain.
DRUG DEVELOPMENT - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer
David-Alexandre C. Gros, MD, explains how researchers are targeting strategies in immunosuppression that can help donated kidneys remain healthy and viable for much longer post-transplant, thus alleviating the need for repeat transplants and making more organs available for first-time transplant recipients.
MODIFIED RELEASE - Getting the Right Formula: Using Modified-Release Formulations to Address Complex Challenges in Drug Development
Vanessa Zann, PhD, presents the opportunities and challenges when transitioning from an IR to MR formulation, and reviews the therapeutic benefits and challenges associated with MR formulations, GI physiology environments and API physicochemical properties, technology choices, and how drug developers can achieve translation success.
Arvinas & Pfizer Announce Initial Phase 1b Data From the TACTIVE-U Sub-Study of Vepdegestrant in Combination With Abemaciclib
Arvinas, Inc. and Pfizer Inc. recently announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib…
Ascendia Pharmaceutical Solutions Launched to Meet Drug Development & Manufacturing Needs
Jim Huang, Ph.D., founder and CEO of Ascendia Pharmaceuticals, announces that the pharmaceutical contract development and manufacturing organization (CDMO) has re-branded to Ascendia Pharmaceutical Solutions.…
uniQure Announces Alignment With FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure N.V. recently announced the company reached agreement with the US FDA on key elements of an Accelerated Approval pathway for AMT-130. “We are very…
Zealand Pharma Announces First Participant Enrolled in Phase 2b Trial of Petrelintide in People With Overweight or Obesity
Zealand Pharma A/S recently announced the first participant has been enrolled in ZUPREME-1, a global Phase 2b trial in people with obesity or overweight with…
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate Toward Clinical Development
Eikonizo Therapeutics recently announced it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. In addition to supporting the development…
Immutep Announces Initiation of Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced the initiation of the pivotal TACTI-004 Phase 3 clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L…
